NFE2L2 and cancer: As discussed earlier, transient activation of Nrf2 exhibits protective, anti-carcinogenic, and anti-mutagenic activities on non-malignant cells [160], but constitutive activation promotes therapeutic resistance and aggressive tumorigenic ability, driving malignant progression in cancer cells [161].